

# Snapshot of the COVID-19 Vaccines

Clinical trials show that all available vaccines work extremely well at preventing COVID-19.



## Johnson & Johnson

Adenovirus (viral vector) vaccine

## Pfizer – BioNTech

mRNA vaccines

## Moderna

mRNA vaccines

## Novavax

Protein subunit vaccine

<p><b>How many doses do I need for a primary series?</b></p> <p><b>You are fully protected 2 weeks after completing your primary series</b></p>	<p>For most people <b>18 and older - 1 dose</b></p> <p>For people <b>18 and older with immunocompromise - 2 doses</b>, 1 dose of Johnson &amp; Johnson, followed by a dose of an mRNA vaccine at least 4 weeks after first dose</p>	<p>For people <b>6 months-4 years - 3 doses</b>, 3 weeks after 1<sup>st</sup>, 8 weeks after 2<sup>nd</sup></p> <p>For most people <b>5 and older -2 doses</b>, 3-8 weeks apart</p> <p>For people <b>5 and older with immunocompromise - 3 doses</b>, second dose 3 weeks after first, third dose at least 4 weeks after the second</p>	<p>For most people <b>6 months and older - 2 doses</b>, 4-8 weeks apart</p> <p>For people <b>6 months and older with immunocompromise - 3 doses</b>, second dose 4 weeks after first, third dose at least 4 weeks after second</p>	<p>For most people <b>18 and older - 2 doses</b>, 3-8 weeks apart</p> <p>For people <b>18 and older with immunocompromise - 2 doses</b>, second dose 3 weeks after the first</p>
<p><b>How old do I have to be to get this vaccine?</b></p>	<p>18 years or older</p>	<p>6 months or older</p>	<p>6 months or older</p>	<p>18 years or older</p>
<p><b>When should I get a booster dose?</b></p>	<p>2 months after your last dose - 18 years and older</p>	<p>5 months after your last dose – for most people 5 years and older</p>	<p>5 months after your last dose – for most people 18 years and older</p>	<p>Booster not authorized at this time</p>
<p><b>Who should get a second booster?</b></p>	<p>Anyone 18 and older is eligible for a booster of an mRNA vaccine four months after first booster</p>	<p>Those aged 50+ or with immunocompromise - 4 months after first booster</p>		<p>Second booster not authorized at this time</p>
<p><b>Does this vaccine protect against variants?</b></p>	<p>Yes. So far, studies suggest that the vaccines in use provide protection against circulating variants. Scientists will continue to study new variants.</p>			

	<b>Johnson &amp; Johnson</b>	<b>Pfizer – BioNTech</b>	<b>Moderna</b>	<b>Novavax</b>
<b>What was the efficacy of the vaccine in the clinical trials?</b>	<b>74%</b> protection against any illness <b>85%</b> protection against severe illness <b>100%</b> protection against hospitalizations and death	<b>95%</b> protection against any illness <b>100%</b> protection against death	<b>94%</b> protection against any illness <b>100%</b> protection against death	<b>90%</b> protection against any illness <b>100%</b> protection against death
<b>What are the ingredients?</b>	The vaccine contains the active ingredient of adenovirus, along with fat, salts, and sugars.	The vaccine contains the active ingredient of messenger RNA (mRNA), along with fat, salts, and sugars.	The vaccine contains the active ingredient of messenger RNA (mRNA), along with fat, salts, and sugars.	The vaccine contains the active ingredient of spike glycoprotein, along with fats, salts, and sugars.
<b>Who was included in clinical trials?</b>	<ul style="list-style-type: none"> <li>• 3.3% Asian</li> <li>• 9.5% American Indian or Alaska Native</li> <li>• 19.4% Black/African American</li> <li>• 45% Hispanic/Latinx</li> <li>• 0.2% Native Hawaiian or other Pacific Islander</li> <li>• 5.6% Multiple races</li> <li>• 59% White</li> </ul> <p>41% of global clinical trial participants had one or more underlying health conditions</p>	<ul style="list-style-type: none"> <li>• 4% Asian</li> <li>• 0.6% American Indian or Alaska Native</li> <li>• 10% Black/African American</li> <li>• 26% Hispanic/Latinx</li> <li>• 0.2% Native Hawaiian or other Pacific Islander</li> <li>• 3% Multiple races</li> <li>• 82% White</li> </ul> <p>46.2% of global trial participants had an underlying health condition. 34.8% of participants were obese.</p>	<ul style="list-style-type: none"> <li>• 5% Asian</li> <li>• 1% American Indian or Alaska Native</li> <li>• 10% Black/African American</li> <li>• 20% Hispanic/Latinx</li> <li>• 0.2% Native Hawaiian or other Pacific Islander</li> <li>• 2.1% “of other descent”</li> <li>• 79% White</li> </ul> <p>22% of global trial participants had one high-risk condition and 4% had two or more high-risk conditions</p>	<ul style="list-style-type: none"> <li>• 75% White</li> <li>• 12% Black/African American</li> <li>• 7% American Indian or Alaska Native</li> <li>• 22% Hispanic/Latinx</li> </ul> <p>95% of trial participants were high risk - Either &gt; 65 years with comorbidities or living or working conditions involving known frequent exposure to COVID-19 or densely populated circumstances</p>